HOOKIPA Set for Breakout on Strong Clinical Progress and Strategic Alliances
AI Prediction of HOOKIPA Pharma Inc. Common Stock (HOOK)
HOOKIPA Pharma, a clinical-stage biopharmaceutical company, is poised for potential significant movements in its stock price due to upcoming catalysts and developments. With its focus on immunotherapeutics targeting infectious diseases and cancers using its arenavirus platform, HOOKIPA has shown promise, particularly with its collaborations with major industry players such as Gilead Sciences. The recent acquisition agreement with Gilead to buy out certain antiviral programs adds financial stability and focuses on their cancer treatment pipeline.
HOOKIPA Pharma Inc., specializing in a new class of immunotherapeutics based on an innovative arenavirus platform, has recently streamlined its operations to focus intensively on oncology and infectious disease sectors, notably through strategic collaborations with Gilead Sciences. These partnerships, particularly in advancing programs like HB-500 for HIV treatment, underscore significant progress in their pipeline. The upcoming clinical trials and potential regulatory advancements for their leading candidates, such as eseba-vec for HPV16+ cancers, set the stage for crucial data readouts that could dramatically influence the company's valuation and market presence. Moreover, the financial infusion from Gilead through stock purchases provides a robust monetary cushion, enabling sustained R&D efforts. Investors should closely monitor HOOKIPA’s execution on these clinical milestones and any strategic maneuvers that may enhance their market position or address the competitive pressures in the biopharmaceutical sector.
HOOK Report Information
Prediction Date2025-07-07
Close @ Prediction$1.23
Mkt Cap15m
IPO Date2019-04-18
AI-derived Information
Recent News for HOOK
- Jul 18, 4:05 pm — HOOKIPA Pharma Announces Intention to Voluntarily Delist and Deregister its Common Stock (GlobeNewswire)
- May 23, 10:42 am — Gilead (GILD) to Acquire HOOK for $10 million (Insider Monkey)
- Feb 20, 3:06 pm — HOOKIPA Pharma Inc. ( HOOKIPA ) Statement regarding potential combination for Poolbeg Pharma plc ( Poolbeg ) (GlobeNewswire)
- Jan 31, 7:21 am — Hookipa Pharma announces enrollment completion of Phase 1b HB-500 trial (TipRanks)
- Jan 30, 7:00 am — HOOKIPA Pharma Announces Enrollment Completion of Phase 1b Clinical Trial Evaluating HB-500 for the Treatment of HIV (GlobeNewswire)
- Jan 10, 2:00 am — Poolbeg Pharma plc ( Poolbeg ) and HOOKIPA Pharma Inc. ( HOOKIPA ) Update on Potential Combination of Poolbeg and HOOKIPA (GlobeNewswire)
- Jan 8, 11:23 am — HOOKIPA Pharma Inc - FORM 8 (OPD) (GlobeNewswire)
- Jan 7, 4:05 pm — HOOKIPA Pharma Announces Notice to Shareholders Regarding U.K. Disclosure Requirements (GlobeNewswire)
- Jan 7, 2:00 am — Poolbeg Pharma plc ( Poolbeg ) and HOOKIPA Pharma Inc. ( HOOKIPA ) Update on Potential Combination of Poolbeg and HOOKIPA (GlobeNewswire)
- Jan 6, 2:00 am — HOOKIPA Pharma Inc. ( HOOKIPA ) Rule 2.9 Announcement Amendment (GlobeNewswire)
- Jan 2, 2:00 am — Poolbeg Pharma plc ( Poolbeg or the Company ) Combination of Poolbeg and HOOKIPA Pharma Inc. (GlobeNewswire)
- Nov 22, 6:51 am — Hookipa Pharma price target lowered to $7 from $24 at JMP Securities (TipRanks)
NDAPR events for HOOK
No NDAPR events found.
Welcome to ScanScor. What you're reading is no ordinary summary -- it's the result of a carefully-crafted interactive session with OpenAI's most advanced models crafted from news, trial details, and financial data. This report attempts to maximize the potential for OpenAI's smartest GPT-based analysis engine, guided by tightly structured prompts to expose the forces behind today's market movers and to predict the future.
Disclaimer: This report is for informational purposes only. It does not constitute financial advice. Always do your own research before making any investment.
We decided to close the window early.
📉 Update on HOOKIPA Pharma (HOOK)
⚠️ Status Change — Public Trading Ended
In July, HOOKIPA Pharma Inc. announced its intention to voluntarily delist and deregister its common stock. Since that decision:
This was not a sudden collapse or bankruptcy, but a controlled exit from public markets. Once a company chooses to delist, it typically no longer generates the kind of catalysts, news flow, or trading activity required for ongoing analysis or prediction.
🛑 Why ScanScor is no longer tracking HOOK
Our system relies on active market participation, liquidity, and public catalysts. With those elements gone, HOOK no longer qualifies for predictive modeling.
💬 In short:
Good science, difficult funding environment, and a quiet ending — a reminder that not all biotech stories conclude with fireworks.